CHOICE:Decision Factor of EGFR-TKI in chinese IV NSCLC - CHOICE

Study identifier:D5161R00072

ClinicalTrials.gov identifier:NCT07413757

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A cross-sectional survey-based study using preference elicitation method to assess decision-making impact factor of Chinese patients and physicians for first-line EGFR-TKIs treatment of stage IV NSCLC (CHOICE)

Medical condition

Non-small Cell Lung Cancer

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

590

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 13 Apr 2026
Estimated Primary Completion Date: 22 Jun 2026
Estimated Study Completion Date: 22 Jun 2026

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Feb 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria